subjects who meet any of the following criteria are not eligible for enrollment as study participants: * known allergy or hypersensitivity to sirolimus * inability or refusal to provide informed consent * advanced respiratory support (high flow oxygen ≥ 15 l/min, cpap, non-invasive or invasive mechanical ventilation) * active enrollment in other interventional clinical drug trials. co-enrollment in observational studies and biorepositories is allowed. * pregnant women * breast feeding * on chronic immunosuppression for other medical conditions such as rheumatological disorders, inflammatory bowel disease, or in patients with organ transplants. a list of these medications is provided in section 12.3.4 * any clinically significant medical disease which in the opinion of the investigator precludes the patient from enrolling in the trial, including (but not limited to): * history of liver cirrhosis * end stage renal disease or need for renal replacement therapy * decompensated heart failure * known active tuberculosis or history of incompletely treated tuberculosis * uncontrolled systemic bacterial or fungal infections * active viral infection other than covid-19

subjects who meet any of the following criteria are not eligible for enrollment as study participants: * known allergy or hypersensitivity to sirolimus * inability or refusal to provide informed consent * advanced respiratory support (high flow oxygen ≥ 15 l/min, cpap, non-invasive or invasive mechanical ventilation) * active enrollment in other interventional clinical drug trials. co-enrollment in observational studies and biorepositories is allowed. * pregnant women * breast feeding * on chronic immunosuppression for other medical conditions such as rheumatological disorders, inflammatory bowel disease, or in patients with organ transplants. a list of these medications is provided in section 12.3.4 * any clinically significant medical disease which in the opinion of the investigator precludes the patient from enrolling in the trial, including (but not limited to): * history of liver cirrhosis * end stage renal disease or need for renal replacement therapy * decompensated heart failure * known active tuberculosis or history of incompletely treated tuberculosis * uncontrolled systemic bacterial or fungal infections * active viral infection other than covid-19

subjects who meet any of the following criteria are not eligible for enrollment as study participants: - known allergy or hypersensitivity to sirolimus - inability or refusal to provide informed consent - advanced respiratory support (high flow oxygen ≥ 15 l/min, cpap, non-invasive or invasive mechanical ventilation) - active enrollment in other interventional clinical drug trials. co-enrollment in observational studies and biorepositories is allowed. - pregnant women - breast feeding - on chronic immunosuppression for other medical conditions such as rheumatological disorders, inflammatory bowel disease, or in patients with organ transplants. a list of these medications is provided in section 12.3.4 - any clinically significant medical disease which in the opinion of the investigator precludes the patient from enrolling in the trial, including (but not limited to): - history of liver cirrhosis - end stage renal disease or need for renal replacement therapy - decompensated heart failure - known active tuberculosis or history of incompletely treated tuberculosis - uncontrolled systemic bacterial or fungal infections - active viral infection other than covid-19

subjects who meet any of the following criteria are not eligible for enrollment as study participants: - known allergy or hypersensitivity to sirolimus - inability or refusal to provide informed consent - advanced respiratory support (high flow oxygen ≥ 15 l/min, cpap, non-invasive or invasive mechanical ventilation) - active enrollment in other interventional clinical drug trials. co-enrollment in observational studies and biorepositories is allowed. - pregnant women - breast feeding - on chronic immunosuppression for other medical conditions such as rheumatological disorders, inflammatory bowel disease, or in patients with organ transplants. a list of these medications is provided in section 12.3.4 - any clinically significant medical disease which in the opinion of the investigator precludes the patient from enrolling in the trial, including (but not limited to): - history of liver cirrhosis - end stage renal disease or need for renal replacement therapy - decompensated heart failure - known active tuberculosis or history of incompletely treated tuberculosis - uncontrolled systemic bacterial or fungal infections - active viral infection other than covid-19